CN101313990B - Application of a Chinese medicinal composition in preparing medicament for treating neurosis - Google Patents
Application of a Chinese medicinal composition in preparing medicament for treating neurosis Download PDFInfo
- Publication number
- CN101313990B CN101313990B CN2007101058476A CN200710105847A CN101313990B CN 101313990 B CN101313990 B CN 101313990B CN 2007101058476 A CN2007101058476 A CN 2007101058476A CN 200710105847 A CN200710105847 A CN 200710105847A CN 101313990 B CN101313990 B CN 101313990B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- neurosis
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides an application of a traditional Chinese medicine composition in preparing a medicine for treating psychoneurosis. The psychoneurosis is also known as neurosis; and the manifestations of the syndrome are mainly chest distress, cardiopalmus, short breath, thoracalgia or gastralgia, hiccup, and physical and emotional handicaps such as anxiety, repression, poor sleep quality and so on. The traditional Chinese medicine composition can effectively improve the manifestations.
Description
Technical field
The present invention relates to the application of a kind of Chinese medicine composition in preparation treatment neurosis medicine, belong to the Chinese medicine application.
Background technology
Neurosis is a kind of traditional appellation, and definite designation both at home and abroad is a neurosis at present, and this disease is the general name of the mental illness of one group of brain function imbalance, comprises neurasthenia, hysteria, obsession and anxiety neurosis.
Neurosis occurs in person between twenty and fifty mostly, with the 18-40 age in year be the highest crowd of sickness rate.The women is more than the male, and the main suit is many and disperse, and lacks internal relation, the changeable and objective determination NED of symptom, and health check-up also depletion of YANG gonosome is levied, though this disease does not influence people's life-span, has a strong impact on orthobiosis.Clinically spirit, psychological illness should actively be diagnosed and treat.The primary disease traditional Chinese medical science belongs to the disease of cardiopalmus, hysteria, simulataneous insufficiency and excessive.This medicine utilization traditional Chinese medical science network ens morbi, the generation of cardiopalmus mainly is because deficiency of both QI and YIN causes the network void of heart network not flourish (networks of meridians) and channels stasis of blood resistance (network of venation).Network void is not flourish to have contained unusual and autonomic nervous function unusual of myocardial cell self-disciplining.
Cardiovascular neurosis be the relevant symptom with cardiovascular disease serve as main performance, with the clinical syndrome of nervous symptoms, it is neurosal a kind of specific type, be more common in middle aged women, 30～40 years old age, be one of common clinically cardiovascular disease, account for and have cardiovascular symptom patient's 10%.Primary disease objective determination NED, no organic heart disease has nerve and hormonal system, especially autonomic nervous function imbalance according to (the common sinus tachycardia of electrocardiogram) on the pathology in the pathogenic process.Diseases such as clinical manifestation is cardiopalmus, chest pain, breathe hard, weak, insomnia and dreamful sleep.Often increase the weight of because of overwork, psychic trauma or when excited, bad during state of an illness fashion, protracted course of disease, to the patient bring very big misery [Hu Xiujuan, Chen Guimin. Ge Hong Tonga flavor treatment cardiovascular neurosis 23 routine observation of curative effect. clinical and The Journal of Experimental Medicine .2006 in March the 5th volume. the 3rd phase: 231].
The gastrointestinal neurosis is more common clinically a kind of in the somatoform disorder, mainly shows as digestive tract neurosis symptom and malfunction based on gastrointestinal tract, as: vomiting, acid regurgitation, belch, epigastric discomfort, anorexia, pain.The patient is except gastrointestinal symptoms, performance [Feng Weixun such as anxiety, depression, irritability, insomnia, anxiety, dizziness are arranged more, Li Hong. bupleurum powder for relieving liver-qi coupling citalopram hydrobromate treatment gastrointestinal neurosis 63 examples. Chinese combination of Chinese and Western medicine digestion magazine, 2005, (05): 335-336].
Skin neurosis is the skin pruritus that is caused by psychological factor, and such skin pruritus has only skin pruritus clinically and do not have the primary cutaneous infringement, simultaneously with performances such as anxiety, depression, irritability, insomnia, anxiety, dizzinesses.
Chinese patent ZL02146572.X discloses a kind of pharmaceutical composition for the treatment of Coronary heart disease ventricular early throb and preparation method thereof.The neurosal application of unexposed this medicine composite for curing of this patent, the present invention have been done further research back and have been confirmed that Chinese medicine composition of the present invention has good curing and improvement effect to neurosis on the basis of this patented technology.The disclosed content of Chinese patent ZL02146572.X quotes in full at this.
Summary of the invention
The invention provides the application of a kind of Chinese medicine composition in preparation treatment neurosis medicine, it is characterized in that this Chinese medicine composition is made by following bulk drugs:
Radix Ginseng 45-180 part, Radix Ophiopogonis 50-200 part, Fructus Corni 125-450 part, Radix Salviae Miltiorrhizae 125-450 part, Semen Ziziphi Spinosae (parched) 95-400 part, Herba Taxilli 95-400 part, Radix Paeoniae Rubra 45-200 part, Eupolyphaga Seu Steleophaga 35-150 part, Radix Et Rhizoma Nardostachyos 45-200 part, Rhizoma Coptidis 25-90 part, Fructus Schisandrae Sphenantherae 35-150 part, Os Draconis 75-300 part;
The weight ratio of crude drug is preferably in the Chinese medicine composition of the present invention: 89 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 224 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 75 parts of Eupolyphaga Seu Steleophagas, 89 parts of Radix Et Rhizoma Nardostachyos, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis;
The weight ratio of crude drug also is preferably in the Chinese medicine composition of the present invention: 45 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 225 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 45 parts of Radix Et Rhizoma Nardostachyos, 35 parts of Eupolyphaga Seu Steleophagas, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis;
The weight ratio of crude drug also is preferably in the Chinese medicine composition of the present invention: 90 parts of Radix Ginsengs, 135 parts of Radix Ophiopogonis, 270 parts of Fructus Corni, 200 parts of Radix Salviae Miltiorrhizaes, 150 parts of Semen Ziziphi Spinosae (parched)s, 150 parts of Herba Taxillis, 100 parts of Radix Paeoniae Rubra, 100 parts of Eupolyphaga Seu Steleophagas, 95 parts of Radix Et Rhizoma Nardostachyos, 60 parts of Rhizoma Coptidis, 75 parts of Fructus Schisandrae Sphenantheraes, 150 parts of Os Draconis;
In the application of the present invention, preparation technology that can be routinely (such as model Bi Ting " pharmacy of Chinese materia medica " (Shanghai Science Press 1997 December the 1st edition) record) handle the crude drug of Chinese medicine composition of the present invention to obtain its active component, preferably, the active component of this Chinese medicine composition can be made by the following step:
A) people participates in 8 times of amount 70% alcohol reflux three times, and merge extractive liquid, filters, and concentrates, and oven dry is ground into fine powder;
B) Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos add 8 times of amount 70% alcohol reflux 3 times jointly, and merge extractive liquid, filters, and reclaims ethanol;
C) Eupolyph aga sinesis Walker is broken into fine powder;
D) Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis decoct with water 2 times, and merge extractive liquid, filters, with the extracting solution merging behind the step b) recovery ethanol, simmer down to extractum;
E) with step d) gained extractum, add the fine drug powder of step c) gained, oven dry is ground into fine powder, adds step a) gained fine drug powder, and mixing promptly gets this Chinese medicine composition active component.
The invention also discloses that to contain above-mentioned Chinese medicine composition be capsule, tablet, electuary, powder, soft capsule, drop pill or oral liquid as the pharmaceutical preparation of active component.
In the Chinese medicine composition of the present invention, as the latin name of the crude drug of active component and processing method thereof from " Chinese medicine voluminous dictionary " (in July, 1977, front page, Shanghai science tech publishing house) and " Chinese pharmacopoeia (version in 2005, Chemical Industry Press).
Chinese medicine composition of the present invention can also be routinely preparation technology, for example, the preparation process of Fan Biting " pharmacy of Chinese materia medica " (Shanghai Science Press 1997 December the 1st edition) record, make the acceptable any conventional dosage form of pharmaceutics, for example capsule, tablet, electuary, powder, soft capsule, drop pill or oral liquid etc.For described dosage form can be realized, need when these dosage forms of preparation, to add the pharmacy acceptable auxiliary, for example: filler, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic, substrate etc.Filler comprises: starch, pregelatinized Starch, lactose, mannitol, chitin, microcrystalline Cellulose, sucrose etc.; Disintegrating agent comprises: starch, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose etc.; Lubricant comprises: magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc.; Suspending agent comprises: polyvinylpyrrolidone, microcrystalline Cellulose, sucrose, agar, hydroxypropyl emthylcellulose etc.; Binding agent comprises, starch slurry, polyvinylpyrrolidone, hydroxypropyl emthylcellulose etc.; Sweeting agent comprises: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc.; Correctives comprises: sweeting agent and various essence; Antiseptic comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, fixed, the Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods of acetic acid chloroethene; Substrate comprises: PEG6000, PEG4000, insect wax etc.
The invention provides the application of a kind of Chinese medicine composition in preparation treatment neurosis medicine, preferably, described neurosis is Dalosta syndrome, gastrointestinal neurosis, skin neurosis.
The invention provides the application of a kind of Chinese medicine composition in preparation treatment neurosis medicine, preferably, described neurosis is neurasthenia, hysteria, obsession or anxiety neurosis.
The consumption of Chinese medicine composition of the present invention by active component crude drug gross weight, was 7-28 gram/days, but takes every day once, preferably divided and took for 2-4 time.
The specific embodiment
Following embodiment is used to illustrate the preparation of Chinese medicine composition of the present invention, but it can not constitute any restriction to scope of the present invention.
Embodiment 1
For the ease of the application of this Chinese medicine composition, this Chinese medicine composition is prepared as capsule
Write out a prescription: Radix Ginseng 89 restrains, restrain Radix Ophiopogonis 112, Fructus Corni 224 restrains, Radix Salviae Miltiorrhizae 224 restrains, Semen Ziziphi Spinosae (parched) 186 restrains, Herba Taxilli 186 restrains, Radix Paeoniae Rubra 89 restrains, Eupolyphaga Seu Steleophaga 75 restrains, Radix Et Rhizoma Nardostachyos 89 restrains, Rhizoma Coptidis 45 restrains, Fructus Schisandrae Sphenantherae 67 restrains, Os Draconis 149 restrain
Preparation method:
A) people participates in 8 times of amount 70% alcohol reflux three times, and 3 hours for the first time, each 2 hours later on, merge extractive liquid, filtered, and concentrates, and oven dry is ground into 80 order fine powders;
B) Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos add 8 times of amount 70% alcohol reflux 3 times jointly, and merge extractive liquid, filters, and reclaims ethanol;
C) Eupolyph aga sinesis Walker is broken into 80 order fine powders;
D) Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis decoct with water 2 times, and merge extractive liquid, filters, with the extracting solution merging behind the step b) recovery ethanol, simmer down to extractum;
E) with step d) gained extractum, add the fine drug powder of step c) gained, oven dry is ground into 80 order fine powders, adds step a) gained fine drug powder, mixing, 1000 capsules of packing into.
Usage and consumption: oral.One time 2～4,3 times on the one.
Test example 1
The clinical trial of traditional Chinese medicine composition for treating cardiovascular neurosis of the present invention.
For illustrating the clinical efficacy of traditional Chinese medicine composition for treating Dalosta syndrome of the present invention, use the capsule (to call medicine of the present invention in the following text) that makes by embodiment 1 method to carry out following clinical trial.
1. material and method
1.1 object of study
Moving in the intracardiac 103 routine cardiovascular neurosis patients of section of hospital (Hebei Medical University is attached to mountain range hospital) year February in November calendar year 2001～2006 is selected object, 20～51 years old age, average (39.1 ± 3.3) year, wherein male 40 examples, women 63 examples; Course of disease February～11 year, average course of disease 2.06.
Inclusion criteria: all main suit's cardiopalmus, dyspnea, precordialgia or heart autonomic nervous dysfunction symptom (hyperhidrosis, brothers feel cold, both hands tremble, frequent micturition etc.), follow dreaminess, insomnia, vexed, dizzy, tinnitus etc.; By detailed physical examination and necessary accessory examinations, get rid of various organic heart diseasies; Obtain patient and family members' thereof informed consent.
Exclusion standard: important organ illness such as brain, lung, liver, kidney are arranged; Patient and family members thereof disagree with into electing object of study as.
Grouping: the 110 routine patients that will be selected in are divided into 2 groups at random, experimental group (53 example) and matched group (50 example), and two groups are in sex, age, the state of an illness, the course of disease etc. just and difference not statistically significant (P〉0.05).Has comparability.
1.2 Therapeutic Method
Inactive other anti-insomnia medicine of treatment the last fortnight.
Treatment group: adopt medicine of the present invention (Hebei Yiling Pharmaceutical Research Institute provides) treatment.Every day 3 times, each 4, in 4 weeks of logotype, followed up a case by regular visits to 4 months.
Matched group: give stable (2.5～5mg/ time, 3 times/day) (Shandong Xinhua Pharmaceutical Factory), VB1 (10～30mg/ time, 3 times/day) oral 4 weeks of logotype of (Shandong Xinhua Pharmaceutical Factory), oryzanol (10mg/ time, 3 times/day) (Shijiazhuang City Condar pharmaceutical factory), followed up a case by regular visits to 4 months.
1.3 the evaluation of curative effect
Curative effect is divided into healing, improvement and invalid 3 grades.
Cure: subjective symptoms all disappears, and does not influence work and life; Take a turn for the better: subjective symptoms partly disappears, slight effect work and life; Invalid: subjective symptoms does not have improvement or increases the weight of.
1.4 statistical method
All data typing SPSS11 statistical softwares, the statistical analysis of employing Wilcoxon rank test the carrying out group difference of effectiveness adopts x
2The statistical analysis of total effective rate group difference is carried out in check, is that difference has statistical significance with P＜0.05.
1.5 result
Relatively seeing the following form of two groups of patient's one curative effects
The comparison sheet of two groups of patient's curative effects
Example (%)
1.6 conclusion:
Curative effect by the visible test group of above-mentioned analytic statistics result obviously is better than matched group, and the total effective rate test group also obviously is better than matched group, and visible medicine of the present invention can effectively be treated Dalosta syndrome.
Test example 2
The neurosal clinical trial of traditional Chinese medicine composition for treating gastrointestinal of the present invention.
For illustrating the clinical efficacy of traditional Chinese medicine composition for treating gastrointestinal neurosis of the present invention, use the capsule (to call medicine of the present invention in the following text) that makes by embodiment 1 method to carry out following clinical trial.
1. material and method
1.1 object of study
Selected patient be between calendar year 2001 to 2006 year the attached outpatient of Hebei Medical University with the Neurology Department diagnosis and treatment of mountain range hospital, all information person is totally 76 examples, wherein male 27 examples, women 49 examples; 18～57 years old age, average 35.4 ± 10.2 years old; The course of disease 6 months～4.5 years, average 2.3 ± 1.8 years;
Inclusion criteria: meet the gastrointestinal criteria for neurosis, the patient is chief complaint with the symptom of gastrointestinal disease, but no any organic change such as gastrointestinal mirror, ultrasonic and lab testing; The drug use history that is a cup too low or inactive psychotropic drugs are more than 2 weeks; Obtain patient and family members' thereof informed consent.
Exclusion standard: have gastrointestinal mirror, ultrasonic and lab testing to suspect any organic change; Important organ illness such as brain, lung, liver, kidney; Patient and family members thereof disagree with into electing object of study as.
Grouping: the 76 routine patients that will be selected in are divided into 2 groups at random, experimental group (39 example) and matched group (37 example), and two groups are in sex, age, the state of an illness, the course of disease etc. just and difference not statistically significant (P〉0.05).Has comparability.
1.2 Therapeutic Method
Inactive other psychotropic drugs of treatment the last fortnight.
Treatment group: adopt medicine of the present invention (Hebei Yiling Pharmaceutical Research Institute provides) treatment.Every day 3 times, each 4, in 4 weeks of logotype, followed up a case by regular visits to 4 months.
Matched group: give oryzanol tablets (production of Shijiazhuang City Condar pharmaceutical factory) every day 3 times, each 10mg in 4 weeks of logotype, followed up a case by regular visits to 4 months.
1.3 the evaluation of curative effect
Curative effect is divided into healing, improvement and invalid 3 grades.
Cure: subjective symptoms all disappears, and does not influence work and life; Take a turn for the better: subjective symptoms partly disappears, slight effect work and life; Invalid: subjective symptoms does not have improvement or increases the weight of.
1.4 statistical method
All data typing SPSS11 statistical softwares, the statistical analysis of employing Wilcoxon rank test the carrying out group difference of effectiveness adopts x
2The statistical analysis of total effective rate group difference is carried out in check, is that difference has statistical significance with P＜0.05.
1.5 result
Relatively seeing the following form of two groups of patient's one curative effects
The comparison sheet of two groups of patient's curative effects
Example (%)
1.6 conclusion:
Curative effect by the visible test group of above-mentioned analytic statistics result obviously is better than matched group, and the total effective rate test group also obviously is better than matched group, and visible medicine of the present invention can effectively be treated gastrointestinal neurosis.
Test example 3
The clinical trial of traditional Chinese medicine composition for treating dermatoneurosis of the present invention.
For illustrating the clinical efficacy of traditional Chinese medicine composition for treating skin neurosis of the present invention, use the capsule (to call medicine of the present invention in the following text) that makes by embodiment 1 method to carry out following clinical trial.
1. material and method
1.1 object of study
Selected patient be between 2002 to 2006 the attached outpatient of Hebei Medical University with the Neurology Department diagnosis and treatment of mountain range hospital, all information person is totally 93 examples, wherein male 31 examples, women 62 examples; 21～59 years old age, average 37.2 ± 11.7 years old; The course of disease 2 months～1.5 years, average 0.6 ± 0.8 year;
Inclusion criteria: meet the dermatoneurosis diagnostic criteria, the patient is chief complaint with the symptom of skin pruritus, simultaneously with, simultaneously with performances such as anxiety, depression, irritability, insomnia, anxiety, dizzinesses; But there is not the primary cutaneous infringement; The drug use history that is a cup too low or inactive psychotropic drugs are more than 2 weeks; Obtain patient and family members' thereof informed consent.
Exclusion standard: the primary cutaneous infringement is arranged; Important organ illness such as brain, lung, liver, kidney; Patient and family members thereof disagree with into electing object of study as.
Grouping: the 93 routine patients that will be selected in are divided into 2 groups at random, experimental group (48 example) and matched group (45 example), and two groups are in sex, age, the state of an illness, the course of disease etc. just and difference not statistically significant (P〉0.05).Has comparability.
1.2 Therapeutic Method
Inactive other psychotropic drugs of treatment the last fortnight.
Treatment group: adopt medicine of the present invention (Hebei Yiling Pharmaceutical Research Institute provides) treatment.Every day 3 times, each 4, in 4 weeks of logotype, followed up a case by regular visits to 4 months.
Matched group: give loratadine tablet (production of Shanghai Schering Plough pharmaceutical Co. Ltd) every day 1 time, each 10mg in 4 weeks of logotype, followed up a case by regular visits to 4 months.
1.3 the evaluation of curative effect
Curative effect is divided into healing, improvement and invalid 3 grades.
Cure: subjective symptoms all disappears, and does not influence work and life; Take a turn for the better: subjective symptoms partly disappears, slight effect work and life; Invalid: subjective symptoms does not have improvement or increases the weight of.
1.4 statistical method
All data typing SPSS11 statistical softwares, the statistical analysis of employing Wilcoxon rank test the carrying out group difference of effectiveness adopts x
2The statistical analysis of total effective rate group difference is carried out in check, is that difference has statistical significance with P＜0.05.
1.5 result
Relatively seeing the following form of two groups of patient's one curative effects
The comparison sheet of two groups of patient's curative effects
Example (%)
1.6 conclusion:
Curative effect by the visible test group of above-mentioned analytic statistics result obviously is better than matched group, and the total effective rate test group also obviously is better than matched group, and visible medicine of the present invention can effectively be treated skin neurosis.
Claims (8)
1. the application of Chinese medicine composition in preparation treatment neurosis medicine, this Chinese medicine composition is made by following bulk drugs:
Radix Ginseng 45-180 part, Radix Ophiopogonis 50-200 part, Fructus Corni 125-450 part, Radix Salviae Miltiorrhizae 125-450 part, Semen Ziziphi Spinosae (parched) 95-400 part, Herba Taxilli 95-400 part, Radix Paeoniae Rubra 45-200 part, Eupolyphaga Seu Steleophaga 35-150 part, Radix Et Rhizoma Nardostachyos 45-200 part, Rhizoma Coptidis 25-90 part, Fructus Schisandrae Sphenantherae 35-150 part, Os Draconis 75-300 part;
It is characterized in that described neurosis is Dalosta syndrome, gastrointestinal neurosis or skin neurosis.
2. application as claimed in claim 1 is characterized in that, this Chinese medicine composition is made by following bulk drugs:
89 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 224 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 75 parts of Eupolyphaga Seu Steleophagas, 89 parts of Radix Et Rhizoma Nardostachyos, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
3. application as claimed in claim 1 is characterized in that, this Chinese medicine composition is made by following bulk drugs:
45 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 225 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 45 parts of Radix Et Rhizoma Nardostachyos, 35 parts of Eupolyphaga Seu Steleophagas, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
4. application as claimed in claim 1 is characterized in that, this Chinese medicine composition is made by following bulk drugs:
90 parts of Radix Ginsengs, 135 parts of Radix Ophiopogonis, 270 parts of Fructus Corni, 200 parts of Radix Salviae Miltiorrhizaes, 150 parts of Semen Ziziphi Spinosae (parched)s, 150 parts of Herba Taxillis, 100 parts of Radix Paeoniae Rubra, 100 parts of Eupolyphaga Seu Steleophagas, 95 parts of Radix Et Rhizoma Nardostachyos, 60 parts of Rhizoma Coptidis, 75 parts of Fructus Schisandrae Sphenantheraes, 150 parts of Os Draconis.
5. as each described application among the claim 1-4, it is characterized in that the active component of this Chinese medicine composition is made by the following step:
A) people participates in 8 times of amount 70% alcohol reflux three times, and merge extractive liquid, filters, and concentrates, and oven dry is ground into fine powder;
B) Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos add 8 times of amount 70% alcohol reflux 3 times jointly, and merge extractive liquid, filters, and reclaims ethanol;
C) Eupolyph aga sinesis Walker is broken into fine powder;
D) Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis decoct with water 2 times, and merge extractive liquid, filters, with the extracting solution merging behind the step b) recovery ethanol, simmer down to extractum;
E) with step d) gained extractum, add the fine drug powder of step c) gained, oven dry is ground into fine powder, adds step a) gained fine drug powder, and mixing promptly gets this Chinese medicine composition active component.
6. as each described application among the claim 1-4, it is characterized in that described Chinese medicine composition is capsule, tablet, electuary, powder, drop pill or oral liquid as the pharmaceutical preparation of active component.
7. as each described application among the claim 1-4, it is characterized in that described neurosis is neurasthenia or hysteria or obsession or anxiety neurosis.
8. application as claimed in claim 5 is characterized in that, described neurosis is neurasthenia or hysteria or obsession or anxiety neurosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101058476A CN101313990B (en) | 2007-06-01 | 2007-06-01 | Application of a Chinese medicinal composition in preparing medicament for treating neurosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101058476A CN101313990B (en) | 2007-06-01 | 2007-06-01 | Application of a Chinese medicinal composition in preparing medicament for treating neurosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101313990A CN101313990A (en) | 2008-12-03 |
| CN101313990B true CN101313990B (en) | 2011-12-07 |
Family
ID=40105234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007101058476A Active CN101313990B (en) | 2007-06-01 | 2007-06-01 | Application of a Chinese medicinal composition in preparing medicament for treating neurosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101313990B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010009573A1 (en) * | 2008-07-23 | 2010-01-28 | 河北以岭医药研究院有限公司 | A pharmaceutical composition for regulating the potassium channel in cardiac muscle cell and its preparation method and its uses |
| CN104491513A (en) * | 2014-12-05 | 2015-04-08 | 王婷婷 | Traditional Chinese medicine composition for treating somatoform disorders |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1403148A (en) * | 2002-10-24 | 2003-03-19 | 河北以岭医药研究院有限公司 | Medicines composition for treating coronary heart disease ventricular premature beat and its prepn |
-
2007
- 2007-06-01 CN CN2007101058476A patent/CN101313990B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1403148A (en) * | 2002-10-24 | 2003-03-19 | 河北以岭医药研究院有限公司 | Medicines composition for treating coronary heart disease ventricular premature beat and its prepn |
Non-Patent Citations (4)
| Title |
|---|
| 吴以岭.神经肌肉类疾病的中医药治疗.《药物与人》.1998,第11卷(第2期),全文. * |
| 杨萍 等.中药制剂—肌萎灵注射液对神经干细胞的促分化作用.《神经解剖学杂志》.2005,第21卷(第2期),全文. * |
| 王继明 等.肌萎灵注射液对运动神经元保护作用的实验研究.《首届国际络病学大会论文集》.2005,全文. * |
| 谷春华 等.参松养心胶囊对冠心病室性早搏疗效及心脏自主神经功能的影响.《中国中西医结合杂志》.2005,第25卷(第9期),全文. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101313990A (en) | 2008-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101856482B (en) | Pure Chinese medicinal preparation for treating mental illness and preparation method thereof | |
| CN101584797B (en) | Application of traditional Chinese medicine composition in preparing medicament for treating climacteric syndrome | |
| CN102283951B (en) | Chinese medicinal composition for treating anaphylactoid purpura and thrombocytopenic purpura | |
| CN101607036B (en) | Application of Chinese medicinal composition on in preparing medicament for treating depression | |
| CN104825788A (en) | Application of traditional Chinese medicine composition in preparation of drug for treating transient ischemic attack | |
| CN101584796B (en) | Application of traditional Chinese medicine composition in preparing medicament for treating melancholia | |
| CN101313990B (en) | Application of a Chinese medicinal composition in preparing medicament for treating neurosis | |
| CN101653550B (en) | Chinese medicinal composition in preparation of medicament for treating type II diabetes | |
| CN101167838B (en) | Traditional Chinese medicinal preparation for treating coronary heart disease and angina pectoris and its preparing process | |
| CN101559161B (en) | Application of traditional Chinese medicine composition in preparing medicament for curing tristimania | |
| CN102579804B (en) | Chinese medicine for treating stenocardia | |
| CN105833043A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating primary hypertension | |
| CN101411814B (en) | Use of Chinese medicinal composition in preparing medicament for treating intraventricular block | |
| CN101732469B (en) | Application of Chinese medicinal composition in preparation of medicament for treating aphonia | |
| CN101632729B (en) | Application of Chinese medicinal composition in preparing medicament for treating involution syndrome | |
| CN103638296A (en) | Application of traditional Chinese medicine for treating coronary heart disease | |
| CN101683458B (en) | Application of a traditional Chinese medicine composition in preparation of medicament for treating vertigo | |
| CN101653548B (en) | Chinese medicinal composition in preparation of medicament for treating hypotension | |
| CN101632783A (en) | Application of Chinese medicinal composition in preparing medicament for treating cor pulmonale | |
| CN101653489A (en) | Application of Chinese medicinal composition in preparation of medicament for preventing diabetes | |
| CN101698051B (en) | Application of traditional Chinese medicine composite in preparing medicine treating climacteric syndrome | |
| CN105288410A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and application of traditional Chinese medicine composition | |
| CN103961429B (en) | Traditional Chinese medicine composition having effects of moving qi and invigorating blood circulation and preparation method thereof | |
| CN101396521B (en) | Use of traditional Chinese medicine composition in preparing medicine for treating cerebral circulation insufficiency | |
| CN101607038A (en) | The application of a kind of Chinese medicine composition in preparation Cure for insomnia medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |